Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronen Marmorstein

Showing results (191-200 of 203) with videos related to

Pageof 21
Sort By:
European Journal of Human Genetics : EJHG|May 2, 2023
Expanding the phenotypic spectrum of NAA10-related neurodevelopmental syndrome and NAA15-related neurodevelopmental syndromeGholson J Lyon, Marall Vedaie, Travis Beisheim, et al.
The EMBO Journal|October 25, 2011
MYST protein acetyltransferase activity requires active site lysine autoacetylationHua Yuan, Dorine Rossetto, Hestia Mellert, et al.
ACS Medicinal Chemistry Letters|June 18, 2021
Remodelin Is a Cryptic Assay Interference Chemotype That Does Not Inhibit NAT10-Dependent Cytidine AcetylationJonathan H Shrimp, Yihang Jing, Supuni Thalalla Gamage, et al.
Cancer Discovery|November 17, 2018
PPT1 Promotes Tumor Growth and Is the Molecular Target of Chloroquine Derivatives in CancerVito W Rebecca, Michael C Nicastri, Colin Fennelly, et al.
ACS Medicinal Chemistry Letters|December 30, 2015
Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pK a Polar MoietyChudi O Ndubaku, James J Crawford, Joy Drobnick, et al.
Human Molecular Genetics|February 7, 2020
Phenotypic and biochemical analysis of an international cohort of individuals with variants in NAA10 and NAA15Hanyin Cheng, Leah Gottlieb, Elaine Marchi, et al.
Human Molecular Genetics|May 26, 2019
Phenotypic and biochemical analysis of an international cohort of individuals with variants in NAA10 and NAA15Hanyin Cheng, Leah Gottlieb, Elaine Marchi, et al.
Cancer Research|January 29, 2021
Drugging the "Undruggable" MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood CancersAdam J Wolpaw, Richard Bayliss, Gabriele Büchel, et al.
Elife|August 6, 2021
<i>Naa12</i> compensates for <i>Naa10</i> in mice in the amino-terminal acetylation pathwayHyae Yon Kweon, Mi-Ni Lee, Max Dorfel, et al.
Cell Reports|September 24, 2013
Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanomaJessie Villanueva, Jeffrey R Infante, Clemens Krepler, et al.
Pageof 21

Showing results (191-200 of 203) with videos related to

Sort By:
Pageof 21
European Journal of Human Genetics : EJHG|May 2, 2023
Expanding the phenotypic spectrum of NAA10-related neurodevelopmental syndrome and NAA15-related neurodevelopmental syndromeGholson J Lyon, Marall Vedaie, Travis Beisheim, et al.
The EMBO Journal|October 25, 2011
MYST protein acetyltransferase activity requires active site lysine autoacetylationHua Yuan, Dorine Rossetto, Hestia Mellert, et al.
ACS Medicinal Chemistry Letters|June 18, 2021
Remodelin Is a Cryptic Assay Interference Chemotype That Does Not Inhibit NAT10-Dependent Cytidine AcetylationJonathan H Shrimp, Yihang Jing, Supuni Thalalla Gamage, et al.
Cancer Discovery|November 17, 2018
PPT1 Promotes Tumor Growth and Is the Molecular Target of Chloroquine Derivatives in CancerVito W Rebecca, Michael C Nicastri, Colin Fennelly, et al.
ACS Medicinal Chemistry Letters|December 30, 2015
Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pK a Polar MoietyChudi O Ndubaku, James J Crawford, Joy Drobnick, et al.
Human Molecular Genetics|February 7, 2020
Phenotypic and biochemical analysis of an international cohort of individuals with variants in NAA10 and NAA15Hanyin Cheng, Leah Gottlieb, Elaine Marchi, et al.
Human Molecular Genetics|May 26, 2019
Phenotypic and biochemical analysis of an international cohort of individuals with variants in NAA10 and NAA15Hanyin Cheng, Leah Gottlieb, Elaine Marchi, et al.
Cancer Research|January 29, 2021
Drugging the "Undruggable" MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood CancersAdam J Wolpaw, Richard Bayliss, Gabriele Büchel, et al.
Elife|August 6, 2021
<i>Naa12</i> compensates for <i>Naa10</i> in mice in the amino-terminal acetylation pathwayHyae Yon Kweon, Mi-Ni Lee, Max Dorfel, et al.
Cell Reports|September 24, 2013
Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanomaJessie Villanueva, Jeffrey R Infante, Clemens Krepler, et al.
Pageof 21